The increase was mainly driven by the USD 6.6 billion annual dividend payment, partly offset by USD 1.9 billion free cash flow from continuing operations in Q1 2019. Additional information is provided on Novartis divisions and pipeline of selected compounds in late stage development and a copy of today's earnings call presentation can be found at.https://www.novartis.com/investors/event-calendar. Net sales were USD 11.1 billion (+2%, +7% cc) in the first quarter driven by volume growth of 11 percentage points (cc), mainly from Cosentyx, Entresto, Lutathera, Promacta and Kisqali. According to this study, over the next five years the Donepezil market will register a -1.6% CAGR in terms of revenue, the global market size will reach US$ 830 million by 2024, from US$ 920 million in 2019. In the firm's earnings report filed July 30 for the second quarter ending June 30, 2019, the company reported total revenue of $5.871 billion for Q2/19, of which $5.574 billion was from product sales. « Sandoz se consacre à accroître son portfolio de biosimilaires au Canada et Hyrimoz ... mènent à une substitution non médicale obligatoire et qui auraient été introduites dans toutes les provinces en 2019 (étanercept et infliximab seulement) pourraient générer 239,6 M$ en économies nationales. In addition, Richard oversees the commercial digital platforms across all of GSK's pharmaceutical franchises. [2]  Refers to continuing operations as defined on page 32 of the Condensed Interim Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz (including the US generic oral solids and dermatology portfolio), as well as the continuing corporate functions. For a detailed review of selected projects in confirmatory development, download the complete Novartis Pipeline (PDF 0.1 MB), as of December 31, 2019. Novartis continues to expect the previously-announced divestment of the Sandoz US oral solids and dermatology portfolio to be completed during 2019, pending closing conditions including regulatory approvals. Lannett Company Total Revenue (US$ Million): 2019 Compared with 2018 Figure 96. Third Sandoz biosimilar approved in Canada in past 11 months expanding its biosimilars portfolio to six and highlighting Sandoz commitment to broadening access to biosimilars. The Sandoz pocket book provides a comprehensive overview of our company, our business areas, corporate responsibility work and information about Sandoz as an employer of choice. Unless otherwise noted, all growth rates in this Release refer to same period in prior year. Forecast assumption that no Gilenya generics enter in 2019; however, generic competitors may still launch at risk. 2018. Novartis kept things busy in 2019 as it continued to focus on becoming a … Core operating income amounted to USD 350 million for discontinued operations (-3%, +7% cc) as higher sales and gross margin, as well as discontinuation of depreciation and software amortization from March 1 (USD 30 million) were partly offset by growth investments. 2019 – delivering on our strategy, producing strong finan - cial results, and making a significant impact on society by improving and extending the lives of people across the globe. This exclusive certification for exceptional employee offerings highlights the company’s commitment to build an attractive and rewarding workplace for its employees, with a high-energy and agile culture. In 2019, the Swiss pharmaceutical company Novartis AG’s total revenue amounted to just over 47 billion U.S. dollars. In Q1 2019, Novartis repurchased a total of 2.2 million shares for USD 0.2 billion, including 0.8 million shares (USD 0.1 billion) bought back under the up-to USD 5 billion share buyback announced in June 2018 on the SIX Swiss Exchange second trading line and 1.4 million shares (USD 0.1 billion) repurchased from associates. The Brand Rankings, Top 50 Global Pharma Companies - 2019 by Pharmaceutical Executive Top 50 Global Pharma Companies - 2019 (Pharmaceutical Executive) | Ranking The Brands select Regulated information Regulated information ... 2019: Strong results and a successful transformation. A replay will be available after the live webcast by visiting.https://www.novartis.com/investors/event-calendar, Detailed financial results accompanying this press release are included in the condensed interim financial report at the link below. Sandoz net sales were USD 2.3 billion (-8%, -2% cc) in the first quarter as 9 percentage points (cc) of price erosion mainly in the US, were partially offset by volume growth of 7 percentage points (cc). Excluding the US, net sales grew 4% (cc). Richard Saynor, currently SVP Classic & Established Products, Commercial & Digital Platforms at GSK, brings over 20 years of global leadership experience spanning both generics and established pharmaceutical brands. During his career, Richard has established a successful track record building strong interfaces between commercial and technical operations as well as driving commercial excellence across his organization. The Corporate Fact Sheets provide a comprehensive overview of Novartis overall as well as our divisions (Innovative Medicines, Sandoz), our research organization NIBR, and outline our commitment to associates as well as Corporate Responsibility. Innovative Medicines net sales were USD 8.8 billion (+5%, +10% cc) in the first quarter, as Pharmaceuticals BU grew 11% (cc) mainly driven by Cosentyx and Entresto, and Oncology BU grew 9% (cc) mainly driven by Lutathera, Promacta and Kisqali. Novartis a promis un don mondial allant jusqu’à 130 millions de doses d’hydroxychloroquine, un antipaludique, afin d’apporter son soutien à la lutte contre la pandémie du COVID-19. Strong volume growth was partly offset by the negative impacts of pricing (-3 percentage points cc) and generic competition (-1 percentage point cc). The total number of shares outstanding increased by 11.6 million versus December 31, 2018. Results for discontinued operations in the first quarter of 2019 include a full quarter of results from the Alcon Division and certain Corporate costs directly attributable to Alcon. This site is intended for a global audience. 339 kb EN Invitation Full-Year 2019 Results. These treasury share transactions resulted in an equity increase of USD 0.3 billion while cash inflows and outflows related to share transactions mostly offset each other. We also provide information on discontinued operations. You should not place undue reliance on these statements. PDF document. Readers should not rely upon the information in these pages as current or accurate after their publication dates. Pricing had a negative impact of 1 percentage point (cc). La Belgique est l'un des nombreux pays à bénéficier de ce don. If mid-April exchange rates prevail for the remainder of 2019, the currency impact for the year would be negative 3 percentage points on net sales and negative 3 to 4 percentage points on core operating income. En complément de notre communication en date du 20 décembre 2019 et du 9 janvier 2020, nous vous informons que les spécialités Amoxicilline SANDOZ 1 g, comprimé dispersible (boîtes de 6 et de 14 comprimés) contenant la notice actualisée sont désormais disponibles. About 105,000 people of more than 140 nationalities work at Novartis around the world. New focused medicines company guidance Excluding Alcon and the Sandoz US oral solids and dermatology business from both 2018 and 2019. calcul de leur revenu imposablefédéral et provincial pour l'année d'imposition 2019. Volume contributed 12 percentage points (cc) to sales growth. L’inflammation et les problèmes respiratoires … [1]  Constant currencies (cc), core results and free cash flow are non-IFRS measures. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Novartis remains fully committed to this business until it is divested to Aurobindo. Dr. Reddys Laboratories Total Revenue (US$ Million): 2019 Compared with 2018 … Net loss from discontinued operations amounted to a loss of USD 101 million compared to a net income of USD 58 million in prior year mainly due to higher one-time tax expenses. [1] Continuing operations include the businesses of Innovative Medicines and Sandoz divisions and Corporate activities and discontinued operations include the business of Alcon. Richard is a Pharmacist by training and started his pharma business career as a sales representative at G.D. Searle in the U.K. Underpinning our financial results in the first quarter is a continued focus on key growth drivers including: Net sales of the top 20 Innovative Medicines products in Q1, Strengthen R&D - Key developments from the first quarter, Results from ongoing trials and other highlights. … The spin-off allows shareholders to benefit from a standalone Alcon and a Novartis with capital and management attention fully focused on medicines. The guidance above includes the forecast assumption that no Gilenya generics enter in 2019 in the US. Novartis will conduct a conference call with investors to discuss this news release today at 14:00 Central European time and 8:00 Eastern Time. Core operating income was USD 3.3 billion (+9%, +18% cc) mainly driven by higher Innovative Medicines sales and improved gross margin, partly offset by growth and launch investments, including for Zolgensma. In particular, our expectations could be affected by, among other things: global trends toward healthcare cost containment, including ongoing government, payer and general public pricing and reimbursement pressures and requirements for increased pricing transparency; regulatory actions or delays or government regulation generally, including potential regulatory actions or delays with respect to the proposed transactions or the development of the products described in this release; the potential that the strategic benefits, synergies or opportunities expected from the Alcon and Sandoz transactions may not be realized or may be more difficult or take longer to realize than expected; the inherent uncertainties involved in predicting shareholder returns; the uncertainties inherent in the research and development of new healthcare products, including clinical trial results and additional analysis of existing clinical data; our ability to obtain or maintain proprietary intellectual property protection, including the ultimate extent of the impact on Novartis of the loss of patent protection and exclusivity on key products that commenced in prior years and will continue this year; safety, quality or manufacturing issues; uncertainties regarding actual or potential legal proceedings, including, among others, actual or potential litigation with respect to the proposed transactions, product liability litigation, litigation and investigations regarding sales and marketing practices, intellectual property disputes and government investigations generally; uncertainties involved in the development or adoption of potentially transformational technologies and business models; our performance on environmental, social and governance measures; general political, economic and trade conditions, including uncertainties regarding the effects of ongoing instability in various parts of the world; uncertainties regarding future global exchange rates; uncertainties regarding future demand for our products; uncertainties regarding potential significant breaches of data security or data privacy, or disruptions of our information technology systems; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. This is a decrease of some four billion U.S. dollars compared to the year before. Boston, January 7, 2019 – Sandoz Inc., a Novartis division, and Pear Therapeutics, Inc., announced today the US commercial launch of reSET-O™ for patients with Opioid Use Disorder (OUD). Prior to GSK, Richard held Commercial Operations leadership roles at Sandoz and oversaw a strong expansion of Sandoz' generics business across Asia, Latin America and Turkey. As part of the spin off, Alcon incurred total bank debt of approximately USD 3.5 billion and paid approximately USD 3.1 billion in cash, including payment in satisfaction of certain intercompany indebtedness owed by Alcon and its subsidiaries to Novartis and its affiliates. [3]  The brand name Zolgensma has been provisionally approved by the FDA for the investigational product AVXS-101 (onasemnogene abeparvovec-xioi), but the product itself has not received marketing authorization or BLA approval from any regulatory authorities. Half yearly information. With our strong pipeline, focus on productivity, and commitment to cultural transformation, we are well positioned for growth in 2019 and the future.". Sandoz, a Novartis division, is proud to announce it has been chosen as a top US employer in 2019 by the Top Employers Institute. New focused medicines company guidance Excluding Alcon and the Sandoz US oral solids and dermatology business from both 2018 and 2019. Par Philippine KAUFFMANN - 15 juil. Richard has also built and led successful teams and organizations with a strong focus on inclusive culture and developing talent. Sandoz fait don d’hydroxychloroquine à la Belgique. The estimated impact of exchange rates on our results is provided monthly on our website. See page 32 of the Condensed Interim Financial Report for a full explanation. Find out more at www.novartis.com. Revenue Annual and half yearly information News & announcement Next. Generic competition had a negative impact of 1 percentage point (cc). Core EPS was USD 1.21 (+5%, +13% cc) in line with core net income. Notre mission au sein du groupe Novartis est de mettre à la disposition du plus grand nombre des médicaments de qualité à un prix plus abordable. For a detailed review of selected projects in confirmatory development, download the complete Novartis Pipeline (PDF 0.1 MB), as of December 31, 2019. Download the media releaseEnglish (PDF 0.1 MB )  |  Deutsch (PDF 0.1 MB)  |  Français (PDF 0.1 MB), Watch the media webcast 09:30 CET - 08:30 GMT - 03:30 EST, Download the media presentation (PDF 1.2 MB), Watch the investor webcast14:00 CET - 13:00 GMT - 08:00 EST, Download the investor presentation (PDF 3.6 MB). * Third Sandoz biosimilar approved in … As of March 31, 2019, the net debt increased by USD 5.3 billion to USD 21.5 billion versus December 31, 2018. Balance sheet impacts of the Alcon spin off will be included in the second quarter results. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. He currently manages a USD 10 billion Established Products portfolio which comprises over 350 brands commercialized in over 120 countries. Retaining a good balance between investment in the business, a strong capital structure and attractive shareholder returns remains a priority. See page 32 of the Condensed Interim Financial Report for full explanation, Detailed financial results accompanying this press release are included in the condensed interim financial report at the link below:http://hugin.info/134323/R/2242311/884910.pdf. From a divisional perspective, we expect net sales performance (cc) in 2019 to be as follows: Innovative Medicines: grow mid single digit. The results of this business are included in continuing operations until the time of the divestment. [6]  The brand name Zolgensma has been provisionally approved by the FDA for the investigational product AVXS-101 (onasemnogene abeparvovec-xioi), but the product itself has not received marketing authorization or BLA approval from any regulatory authorities. Please find full media release in English attached and on the following link:http://hugin.info/134323/R/2242311/884922.pdf. This reduced the net debt position of Novartis by approximately USD 3.0 billion. L'ensemble des spécialités précitées contenant les notices actualisées sont désormais disponibles. As part of the strategy to focus Novartis, the Alcon business was spun-off as a separate public company on April 9, following the shareholder vote on February 28. Sandoz Total Revenue (US$ Million): 2019 Compared with 2018 Figure 94. The commentary below focuses on continuing operations including the businesses of Innovative Medicines and Sandoz (including the US generic oral solids and dermatology portfolio), as well as the continuing corporate functions. Our Annual Report 2019 provides a comprehensive overview of Novartis, including our corporate governance, compensation practices, and operating and financial results. This presentation remains on the Novartis website for historical purposes only. 10.2.2 Sandoz Description, Business Overview and Total Revenue 10.2.3 Sandoz Megestrol Sales, Revenue and Gross Margin (2015-2020) 10.2.5 Sandoz Recent Development PDF document. Free cash flow for the total Group amounted to USD 1.8 billion. Novartis aims to offset the dilutive impact from equity based participation plans of associates over the remainder of the year. From a divisional perspective, we expect net sales performance (cc) in 2019 to be as follows: The digital and interactive version of the Annual Review is available here. Core operating income margin in constant currencies increased by 2.6 percentage points; currency had a negative impact of 0.6 percentage points, resulting in a net increase of 2.0 percentage points to 29.3% of net sales.